LifeMD to Report Second Quarter 2023 Financial Results on August 9
NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents...
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company...
ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company...
LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies,...
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial...
Full recruitment secures the target number of completer patientsMultiple primary endpoints include reduction in agitation and aggression and overall disease...
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application (BLA)...
VANCOUVER, British Columbia and LAS VEGAS, July 26, 2023 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV:...
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and...
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy End-of-Phase 2 meeting with FDA...
BURLINGTON, Mass. and JERUSALEM, July 26, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of...
Conference call scheduled for 8:00 a.m. Eastern TimeWALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a...
Constant Therapy Health grants researchers at Boston University and The University of Texas at Austin access to world’s largest speech...
SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology...
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel...
First shipment of D*gg lbs (pronounced “dog pounds”) from the Company’s EU GMP facility in Chatham, Ontario has arrived in...
- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned...
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia...